hotspot -WSS

hotspot

author：comprehensive 2025-09-10 08:41:22 - browse：42

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Study: Spinal cord stimulation helps patients with paralysis walk again

focus

WSS

WATCH: Why do fingernails fall off when they're damaged?

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Health officials lay out plans to cope with respiratory virus season

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Gene therapy has helped boys walk. Can scientists keep it that way?

Gene therapy has helped boys walk. Can scientists keep it that way?

entertainment

hotspot

focus

Bright Health sells Medicare Advantage business to Molina

3 hurdles to bringing medical devices to the U.S. market

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The story of mRNA: From a loose idea to a tool that may help curb Covid

Trump demands the U.S. pay no more for drugs than other countries … again

Vivek Ramaswamy made waves in the debate, much as in biotech

DIEP, the 'gold standard' of breast reconstruction, is under threat

Ask STAT: What do you want to know about ChatGPT in medicine?

Wildfire smoke exposes gaps in outdoor worker protections

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

focus

Why drug prescriptions should include diagnoses

Wegovy improves function in certain heart failure patients

California store owner shot dead in dispute over displaying Pride flag: Police

Meadows told special counsel he could not recall Trump ever declassifying Mar

PBMs are inflating the cost of generic drugs. They must be reined in

Cloning humans is technically possible. It's curious no one has tried

entertainment

focus

leisure time

entertainment